Filing Details

Accession Number:
0001209191-20-027894
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-08 16:22:01
Reporting Period:
2020-05-06
Accepted Time:
2020-05-08 16:22:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1661567 Michael Parini C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Chief Adm, Leg & Bd Off No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-06 1,222 $155.57 28,060 No 4 M Direct
Common Stock Disposition 2020-05-06 273 $270.16 27,787 No 4 S Direct
Common Stock Disposition 2020-05-06 140 $271.64 27,647 No 4 S Direct
Common Stock Disposition 2020-05-06 319 $273.00 27,328 No 4 S Direct
Common Stock Disposition 2020-05-06 420 $273.96 26,908 No 4 S Direct
Common Stock Disposition 2020-05-06 70 $274.73 26,838 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-05-06 1,222 $0.00 1,222 $155.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
8,561 2028-02-05 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $270.16 (range $269.77 to $270.75).
  3. Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $271.64 (range $271.55 to $271.73).
  5. Open market sales reported on this line occurred at a weighted average price of $273.00 (range $272.66 to $273.44).
  6. Open market sales reported on this line occurred at a weighted average price of $273.96 (range $273.68 to $274.31).
  7. The option vests in 16 quarterly installments from 02/06/2018.